NONCONTRACEPTIVE BENEFITS OF LEVONORGESTREL- RELEASING INTRAUTERINE SYSTEM ON ENDOMETRIOSIS
article
OA: closed
CC0
AI-generated summary
The Levonorgestrel Intrauterine System shows efficacy in pain control, reduced bleeding, disease control, and improved quality of life for endometriosis, with potential cardiovascular and bone density benefits.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Objective: Identify non-contraceptive benefits of the Levonorgestrel Intrauterine System in the treatment of endometriosis. Methodology: A search for national and international articles on bases MEDLINE, PubMed and LILACS was performed between January and March of 2014, with key words “endometriose” “SIU-LNG”, “endometriosis” and “LNG-IUS”. Discussion: LNG-IUS seems to have similar efficacy as the GnRH in pain control caused by endometriosis, reducing cronic pelvic pain, dysmenorrhoea and dyspareunia. Shows effect in reducing menstrual bleeding, disease control, increased quality of life and decreased recurrence after laparoscopic surgery. It is observed cardiovascular risk reduction and positive effect on bone mineral density. Conclusion: Treatment with LNGIUS appears to be promising, but randomized trials with larger numbers of participants are needed for recognition as standard treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (19)
- Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis via openalex
- Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system via openalex
- Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases via openalex
- Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis via openalex
- Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging via openalex
- [Effects of progesterone and progestin on expression of regulated on activation, normal T cell expressed and secreted in eutopic endometrium from patients with endometriosis]. via openalex
- Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue via openalex
- Emerging indications for the levonorgestrel‐releasing intrauterine system (LNG‐IUS) via openalex
- Intrauterine devices and adolescents via openalex
- Levonorgestrel‐releasing intrauterine system (Mirena <sup>®</sup> ) and Depot medroxyprogesterone acetate (Depoprovera) as long‐term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial via openalex
- Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS via openalex
- The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis via openalex
- Use of Levonorgestrel Intrauterine System for Medical Indications in Adolescents via openalex
- Use of the Levonorgestrel Intrauterine System in Adolescents with Endometriosis via openalex
- W2119560204 via openalex
- W2007561870 via openalex
- W1998154378 via openalex
- W2164017484 via openalex
- W2289160667 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK